Patient preference and timing for exercise in breast cancer care

Kathleen Sturgeon, Carla Fisher, Gina McShea, Susan Kruse Sullivan, Dahlia Sataloff, Kathryn Schmitz

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Exercise is recommended following cancer diagnosis and may be particularly valuable for women receiving cardiotoxic chemotherapy treatments. We investigated breast cancer patient preference on exercise programming in a prospective manner and retrospectively assessed length of time between diagnosis and chemotherapy initiation. Sixty-seven newly diagnosed breast cancer patients responded to questions regarding exercise programming related to cancer treatment and surveys on current activity level. Additionally, a retrospective chart review was conducted on 500 random breast cancer patients. Age, cancer stage, treatment, and treatment dates were extracted. Women were interested in, or, absolutely wanted to, participate in an exercise program before treatment (76.2%). There was uncertainty regarding willingness to delay treatment; 49.2% were willing to delay their treatment if the program was recommended by their doctors, 41.8% would not, and 9.0% were too unsure to respond. However, women would like to hear information about an exercise program for cancer patients when they are first diagnosed (61.9%). We observed that 64.6% of women were below recommended levels of physical activity; yet, current activity was not associated with an interest in an exercise program or willingness to delay treatment. Retrospectively, we observed an average interval of 72.6 ± 34.6 days between cancer diagnosis and initiation of anthracycline-based chemotherapy treatment, with younger women with more advanced cancer receiving anthracycline-based chemotherapy. Based on patient preference and length of time to chemotherapy initiation, a reasonable next step to promote the current recommendations for exercise could be to integrate exercise into breast cancer care earlier in treatment.

Original languageEnglish (US)
Pages (from-to)507-514
Number of pages8
JournalSupportive Care in Cancer
Volume26
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Patient Preference
Exercise
Breast Neoplasms
Drug Therapy
Therapeutics
Anthracyclines
Neoplasms
Second Primary Neoplasms
Uncertainty

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Sturgeon, Kathleen ; Fisher, Carla ; McShea, Gina ; Sullivan, Susan Kruse ; Sataloff, Dahlia ; Schmitz, Kathryn. / Patient preference and timing for exercise in breast cancer care. In: Supportive Care in Cancer. 2018 ; Vol. 26, No. 2. pp. 507-514.
@article{4b468e01feb54540b59c0d163bbfc5a1,
title = "Patient preference and timing for exercise in breast cancer care",
abstract = "Exercise is recommended following cancer diagnosis and may be particularly valuable for women receiving cardiotoxic chemotherapy treatments. We investigated breast cancer patient preference on exercise programming in a prospective manner and retrospectively assessed length of time between diagnosis and chemotherapy initiation. Sixty-seven newly diagnosed breast cancer patients responded to questions regarding exercise programming related to cancer treatment and surveys on current activity level. Additionally, a retrospective chart review was conducted on 500 random breast cancer patients. Age, cancer stage, treatment, and treatment dates were extracted. Women were interested in, or, absolutely wanted to, participate in an exercise program before treatment (76.2{\%}). There was uncertainty regarding willingness to delay treatment; 49.2{\%} were willing to delay their treatment if the program was recommended by their doctors, 41.8{\%} would not, and 9.0{\%} were too unsure to respond. However, women would like to hear information about an exercise program for cancer patients when they are first diagnosed (61.9{\%}). We observed that 64.6{\%} of women were below recommended levels of physical activity; yet, current activity was not associated with an interest in an exercise program or willingness to delay treatment. Retrospectively, we observed an average interval of 72.6 ± 34.6 days between cancer diagnosis and initiation of anthracycline-based chemotherapy treatment, with younger women with more advanced cancer receiving anthracycline-based chemotherapy. Based on patient preference and length of time to chemotherapy initiation, a reasonable next step to promote the current recommendations for exercise could be to integrate exercise into breast cancer care earlier in treatment.",
author = "Kathleen Sturgeon and Carla Fisher and Gina McShea and Sullivan, {Susan Kruse} and Dahlia Sataloff and Kathryn Schmitz",
year = "2018",
month = "2",
day = "1",
doi = "10.1007/s00520-017-3856-8",
language = "English (US)",
volume = "26",
pages = "507--514",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "2",

}

Patient preference and timing for exercise in breast cancer care. / Sturgeon, Kathleen; Fisher, Carla; McShea, Gina; Sullivan, Susan Kruse; Sataloff, Dahlia; Schmitz, Kathryn.

In: Supportive Care in Cancer, Vol. 26, No. 2, 01.02.2018, p. 507-514.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Patient preference and timing for exercise in breast cancer care

AU - Sturgeon, Kathleen

AU - Fisher, Carla

AU - McShea, Gina

AU - Sullivan, Susan Kruse

AU - Sataloff, Dahlia

AU - Schmitz, Kathryn

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Exercise is recommended following cancer diagnosis and may be particularly valuable for women receiving cardiotoxic chemotherapy treatments. We investigated breast cancer patient preference on exercise programming in a prospective manner and retrospectively assessed length of time between diagnosis and chemotherapy initiation. Sixty-seven newly diagnosed breast cancer patients responded to questions regarding exercise programming related to cancer treatment and surveys on current activity level. Additionally, a retrospective chart review was conducted on 500 random breast cancer patients. Age, cancer stage, treatment, and treatment dates were extracted. Women were interested in, or, absolutely wanted to, participate in an exercise program before treatment (76.2%). There was uncertainty regarding willingness to delay treatment; 49.2% were willing to delay their treatment if the program was recommended by their doctors, 41.8% would not, and 9.0% were too unsure to respond. However, women would like to hear information about an exercise program for cancer patients when they are first diagnosed (61.9%). We observed that 64.6% of women were below recommended levels of physical activity; yet, current activity was not associated with an interest in an exercise program or willingness to delay treatment. Retrospectively, we observed an average interval of 72.6 ± 34.6 days between cancer diagnosis and initiation of anthracycline-based chemotherapy treatment, with younger women with more advanced cancer receiving anthracycline-based chemotherapy. Based on patient preference and length of time to chemotherapy initiation, a reasonable next step to promote the current recommendations for exercise could be to integrate exercise into breast cancer care earlier in treatment.

AB - Exercise is recommended following cancer diagnosis and may be particularly valuable for women receiving cardiotoxic chemotherapy treatments. We investigated breast cancer patient preference on exercise programming in a prospective manner and retrospectively assessed length of time between diagnosis and chemotherapy initiation. Sixty-seven newly diagnosed breast cancer patients responded to questions regarding exercise programming related to cancer treatment and surveys on current activity level. Additionally, a retrospective chart review was conducted on 500 random breast cancer patients. Age, cancer stage, treatment, and treatment dates were extracted. Women were interested in, or, absolutely wanted to, participate in an exercise program before treatment (76.2%). There was uncertainty regarding willingness to delay treatment; 49.2% were willing to delay their treatment if the program was recommended by their doctors, 41.8% would not, and 9.0% were too unsure to respond. However, women would like to hear information about an exercise program for cancer patients when they are first diagnosed (61.9%). We observed that 64.6% of women were below recommended levels of physical activity; yet, current activity was not associated with an interest in an exercise program or willingness to delay treatment. Retrospectively, we observed an average interval of 72.6 ± 34.6 days between cancer diagnosis and initiation of anthracycline-based chemotherapy treatment, with younger women with more advanced cancer receiving anthracycline-based chemotherapy. Based on patient preference and length of time to chemotherapy initiation, a reasonable next step to promote the current recommendations for exercise could be to integrate exercise into breast cancer care earlier in treatment.

UR - http://www.scopus.com/inward/record.url?scp=85028349382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028349382&partnerID=8YFLogxK

U2 - 10.1007/s00520-017-3856-8

DO - 10.1007/s00520-017-3856-8

M3 - Article

C2 - 28840334

AN - SCOPUS:85028349382

VL - 26

SP - 507

EP - 514

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 2

ER -